4//SEC Filing
Rolke James 4
Accession 0000920465-20-000045
CIK 0000920465other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 6:08 PM ET
Size
7.0 KB
Accession
0000920465-20-000045
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-03-31$3.57/sh+229$818→ 81,147 total - Award
Stock Option (Right to Buy)
2020-03-31+229→ 229 totalExercise: $4.20Exp: 2030-03-31→ Common Stock (229 underlying)
Footnotes (2)
- [F1]These shares were acquired on 03/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Documents
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
Related Parties
1- filerCIK 0001693858
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 6:08 PM ET
- Size
- 7.0 KB